Nouscom
is a Switzerland-based immuno-oncology company that researches and develops personalized immunotherapies for the treatment of cancer... Read moreNouscom
is a Switzerland-based immuno-oncology company that researches and develops personalized immunotherapies for the treatment of cancer... Read more
News
Jul 21, 2026
PharmaTimes
Nouscom: Nouscom to present retreatment data in Lynch Syndrome at ESMO 2026
Jun 01, 2026
GlobalNewswire
Press Release: Nouscom : Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers
Jan 16, 2026
StreetInsider
Press Release: Nouscom : Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
Nov 07, 2025
GlobalNewswire
Press Release: Nouscom : Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
Oct 13, 2025
Startupticker
Nouscom: Clinical milestones bring startups closer to launching new therapies
Oct 12, 2025
GlobalNewswire
Press Release: Nouscom : Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 2025
May 09, 2025
Startupticker
Nouscom: Milestones achievements for life sciences startups
Apr 29, 2025
GlobalNewswire
Press Release: Nouscom : Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
Mar 26, 2025
PharmaTimes
Nouscom: Nouscom reveals promising results for lynch syndrome immunotherapy
Nov 19, 2024
StreetInsider
Press Release: Nouscom : Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
Nouscom Competitors
1
2
3
4
5
6
7